A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)
Launched by NEWPORT PHARMACEUTICALS INTERNATIONAL · Aug 30, 2001
Trial Information
Current as of March 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- • Exclusion Criteria
- Concurrent Medication:
- Excluded:
- • Cardiac glycosides.
- Patients with the following are excluded:
- • AIDS.
- • Presenting with chronic candida infection-colo/rectal, oral/pharyngeal, cutaneous (finger/toenails) - for = or \> 3 months who have not responded to therapy.
- • Critical illness.
- • Hemophilia.
- Prior Medication:
- Excluded within 1 month of study entry:
- • Steroids.
- • Cytotoxic immunosuppressive agents.
- • Radiotherapy and/or systemic antiviral medication.
- • Immunomodulators (including Isoprinosine).
- Prior Treatment:
- Excluded within 1 month of study entry:
- • Radiotherapy.
- • History of gout, uric acid urolithiasis, uric acid nephrolithiasis, or renal dysfunction.
- • Lymphoid malignancy.
- • Homosexual male patients with AIDS related complex (ARC).
- • Current IV drug abuse.
About Newport Pharmaceuticals International
Newport Pharmaceuticals International is a leading biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs across various therapeutic areas. With a strong focus on research and development, Newport Pharmaceuticals harnesses cutting-edge science and technology to create effective treatments aimed at improving patient outcomes. The company is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring safety and efficacy while fostering collaboration with healthcare professionals and regulatory bodies. Through its dedication to innovation and excellence, Newport Pharmaceuticals International strives to make a meaningful impact on global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Laguna Hills, California, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials